Tidemark’s Pacific Biosciences PACB Stock Holding History

Tidemark’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.18K	Hold	700	–	–	﹤0.01%	729
2026 Q1	$924	Hold	700	–	–	﹤0.01%	705
2025 Q4	$1.31K	Hold	700	–	–	﹤0.01%	598
2025 Q3	$896	Hold	700	–	–	﹤0.01%	639
2025 Q2	$868	Hold	700	–	–	﹤0.01%	652
2025 Q1	$826	Hold	700	–	–	﹤0.01%	656
2024 Q4	$1.28K	Hold	700	–	–	﹤0.01%	609
2024 Q3	$1.19K	Sell	700 -41	-6%	-$67	﹤0.01%	573
2024 Q2	$1.01K	Hold	741	–	–	﹤0.01%	564
2024 Q1	$2.78K	Hold	741	–	–	﹤0.01%	575
2023 Q4	$7.27K	Buy	+741	New	+$6.06K	﹤0.01%	455

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tidemark's PACB Position: Q2 2026 in Review

Tidemark held its Pacific Biosciences (PACB) position steady in Q2 2026 at 700 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #729.

Tidemark first reported a position in PACB in Q4 2023 and has held it in 11 quarters since. The position peaked at $7.27K in Q4 2023. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Tidemark held 700 shares of Pacific Biosciences worth $1.18K as of Q2 2026.
Tidemark left its Pacific Biosciences share count unchanged in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #729 holding.
Tidemark first reported a position in Pacific Biosciences in Q4 2023 and has held it in 11 quarters since.
Tidemark's Pacific Biosciences position peaked at $7.27K in Q4 2023.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.